A peptide-centric quantitative proteomics dataset for the phenotypic assessment of Alzheimer’s disease

Gennifer E. Merrihew, Jea Park, Deanna Plubell, Brian C. Searle, C. Dirk Keene, Eric B. Larson, Randall Bateman, Richard J. Perrin, Jasmeer P. Chhatwal, Martin R. Farlow, Catriona A. McLean, Bernardino Ghetti, Kathy L. Newell, Matthew P. Frosch, Thomas J. Montine, Michael J. MacCoss

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Alzheimer’s disease (AD) is a looming public health disaster with limited interventions. Alzheimer’s is a complex disease that can present with or without causative mutations and can be accompanied by a range of age-related comorbidities. This diverse presentation makes it difficult to study molecular changes specific to AD. To better understand the molecular signatures of disease we constructed a unique human brain sample cohort inclusive of autosomal dominant AD dementia (ADD), sporadic ADD, and those without dementia but with high AD histopathologic burden, and cognitively normal individuals with no/minimal AD histopathologic burden. All samples are clinically well characterized, and brain tissue was preserved postmortem by rapid autopsy. Samples from four brain regions were processed and analyzed by data-independent acquisition LC-MS/MS. Here we present a high-quality quantitative dataset at the peptide and protein level for each brain region. Multiple internal and external control strategies were included in this experiment to ensure data quality. All data are deposited in the ProteomeXchange repositories and available from each step of our processing.

Original languageEnglish
Article number206
JournalScientific data
Issue number1
StatePublished - Dec 2023


Dive into the research topics of 'A peptide-centric quantitative proteomics dataset for the phenotypic assessment of Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this